MedTrace Logo

High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes

NCT07118670 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-03-18

No results posted yet for this study

Summary

The purpose of this Phase 4 study is to evaluate the safety of aflibercept 8mg in patients with proliferative diabetic retinopathy without center-involved diabetic macular edema.

Conditions

  • Proliferative Diabetic Retinopathy (PDR)

Interventions

DRUG

Aflibercept 8mg

Solution in Vial, intravitreal (IVT) injection

Sponsors & Collaborators

  • Greater Houston Retina Research

    collaborator OTHER

  • Edward Wood, MD

    lead OTHER

Principal Investigators

  • Edward Wood, MD · Retina Consultants of Texas

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-08
Primary Completion
2028-02-29
Completion
2028-04-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07118670 on ClinicalTrials.gov